Tue, Apr 22, 10:02 AM (31 days ago)
**Cannabis Bioscience International Holdings, Inc. (CBIS) Q1 2025 Financial Summary** **Financial Health and Performance:** Cannabis Bioscience International Holdings, Inc. (CBIS) reported a challenging quarter with significant financial losses and operational uncertainties. The company's cash position declined to $548,000 from $755,000 in the previous quarter, reflecting ongoing liquidity issues. Accounts receivable also decreased to $2,640,000, indicating potential delays in revenue recognition. **Revenue and Profit Margins:** Revenue for the quarter was $14,931,000, down from $36,411,000 in the same period last year, primarily due to a decrease in clinical trial revenues. The gross loss was $4,465,000, a significant decline from the gross profit of $24,602,000 reported in the previous year. Operating expenses were $149,679,000, slightly lower than the $184,573,000 reported last year, but still high relative to revenue. **Cash Flow:** The company reported a net cash used in operations of $209,653,000, an improvement from the $304,943,000 used in the previous year. Financing activities provided $209,445,000 in cash, helping to offset operational losses. However, the company's cash position remains precarious, with only $548,000 in cash and cash equivalents at the end of the quarter. **Earnings and Losses:** Net loss for the quarter was $192,443,000, slightly improved from the $209,192,000 loss reported in the same period last year. The company's accumulated deficiency increased to $5,671,156,000, highlighting ongoing financial struggles. **Trends and Uncertainties:** CBIS faces substantial uncertainties, including recurring losses, negative working capital, and significant debt. The company's ability to continue as a going concern is dependent on successful execution of its operating plan, which includes expanding operations and securing additional financing. The company's history of financial losses and high operating expenses raises concerns about its long-term viability. **Future Operations Impact:** CBIS must address its liquidity issues and reduce operating expenses to improve financial health. The company's reliance on clinical trial revenues and educational services may limit growth potential. Securing additional financing and diversifying revenue streams will be crucial for future success. The company's management must also address concerns about internal controls and financial reporting to regain investor confidence. **Conclusion:** CBIS reported a challenging quarter with significant financial losses and operational uncertainties. The company's cash position declined, and revenue decreased, reflecting ongoing liquidity issues. To improve financial health, CBIS must address its liquidity issues, reduce operating expenses, and secure additional financing. The company's future success will depend on its ability to execute its operating plan and regain investor confidence.